Clinical Trial Update: CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for a CD19-targeted CAR-T cell therapy in relapsed/refractory CD19+ B-cell leukemias and lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Leukemia B-cell
• Leukemia Lymphocytic Chronic B-cell
• Lymphoma B-cell
• Lymphoma Large B-cell Diffuse

Drugs mentioned

• CD19-targeted CAR-T cell therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Leukemia, Lymphoma, Large B-Cell, Diffuse | Phase 1, Phase 2 | Status: UNKNOWN